Due to the recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Global Digital Health Investment and Financing OverviewDecentralized Patient Network Humanscape Completes Approximately $15.34 Million Extended Series C FinancingOn December 21, decentralized patient network Humanscape completed an extended Series C funding round, raising 20 billion Korean won (approximately $15.34 million), with participation from the Korea Development Bank, Hana Securities, and Hana Venture Investment. To date, the total amount raised in Humanscape's Series C funding has reached 40 billion Korean won (approximately $30.69 million). Humanscape helps patients manage their conditions through intellectual and emotional interactions based on community activities.CDMO Service Provider Kossel Completes Over 100 Million Yuan in Series B FinancingOn December 25, Kossel Medtech (Suzhou) Co., Ltd., a CDMO service provider, completed a B-round financing of over 100 million yuan, led by Fortune Venture Capital, with participation from Su Chuantou ▪ Guofa Venture Capital, Su Gaoxin Shares, and Medpark. This round of financing will help the company deepen its platformization and internationalization layout in vascular intervention, enrich its product pipeline, and expand production bases.Gynecological Tumor Early Screening Test Product Developer Cispoly Announces Completion of Over 100 Million Yuan in Series B FinancingOn December 27, Cispoly, a developer of early screening detection products for gynecological tumors, announced the completion of a Series B financing round exceeding 100 million yuan. This round was led by Prosperity7 Ventures, a diversified growth fund under Aramco Ventures. The funds will strongly support the company’s global business expansion, product development, registration applications, public health management, and consumer healthcare sector growth, providing efficient solutions for numerous users.Neuroscience AI-Assisted Diagnosis and Treatment Product Developer Union Strong Completes Nearly RMB100 Million D-Round FinancingRecently, Union Strong, an AI-assisted diagnosis and treatment product developer in the field of neuroscience, has completed a nearly RMB 100 million D-round financing. This round of financing was directly invested by the Yantai Biomedical and Health Industry Development Fund. The funds will mainly be used for industrial construction, research and development innovation, and market expansion in the field of intelligent diagnosis and treatment of cerebrovascular diseases, helping the company achieve greater breakthroughs and development.Gene Sequencing Technology Developer QitanTech Completes Nearly 100 Million Yuan in C+ Round FinancingRecently, QitanTech, a gene sequencing technology developer, has completed a nearly RMB 100 million C+ round of financing, invested by Source Capital and Chengdu BioCity Fund (Guosheng Capital). This round of financing will be used for product technology research and development, production capacity expansion, market development, etc. The company will continue to enhance commercialization, improve the product portfolio, enhance delivery capabilities, and further explore application scenarios, providing users with an easy-to-use domestically produced nanopore sequencing platform.Gene Testing Service Provider We Health Biomedical Completes Nearly 100 Million Yuan B1 Round FinancingOn December 27, We Health Biomedical, a genetic testing service provider, completed a nearly RMB 100 million B1 round of financing, with investors including Shanghai Qingchuang Rui Zhi Group and others. This round of financing will further solidify the company's product layout and registration applications in the direction of genetic disease testing and tertiary prevention of birth defects in China, and expand the company’s LDT laboratory presence across China.Epigenetic Therapy Developer Celgene Pharmaceuticals Completes Nearly 100 Million Yuan A+ Round FinancingOn December 25, Epigenetic Therapeutics R&D company CellArk completed a nearly RMB100 million Series A+ financing round. This round was co-led by Fortune Venture Capital Fund and Hangzhou Heda Fund, and the funds will mainly be used to accelerate the clinical development of multiple products from CellArk and continuously enhance the company's EpigenPLUS epigenetics technology R&D platform.Zhongke Ruiji, a one-stop solution provider for regenerative medicine, completes tens of millions of yuan in A++ round financingRecently, Zhongke Ruiji (Haining) Biotechnology Co., Ltd., a one-stop solution provider in regenerative medicine, has completed a multi-million yuan A++ round of financing, led by "Haining New Vision Yuxiu Fund" and "Haining Juanhu Dream Mother Fund" under Zijin Harbor Capital, with an investment of tens of millions of yuan. The funds from this round of financing will be mainly used for the company's investment in product pipeline construction in East China, R&D investment in various product pipelines, as well as the expansion of domestic and international sales channels.Yishan Medical, a Developer and Manufacturer of Maternal and Child Health Management Equipment, Completes Multi-Million Dollar Pre-A Round FinancingRecently, Yishan Medical, a developer and manufacturer of maternal and child health management equipment, has completed a multi-million-dollar Pre-A round of financing. This round was led by Singapore's Capital Asia Investments. The funds will mainly be used to consolidate and strengthen the company’s market position in fetal and neonatal health management and to promote its business expansion and market exploration in global markets.Neurodome, a developer of neuromodulation products, has completed a Pre-A round of financing worth tens of millions of yuan.On December 27, Neurodome, a neuro-modulation technology developer, completed a Pre-A round of financing worth tens of millions of yuan. This round was co-led by Shaanxi Investment Growth Fund and Yuanhe Origin Point, with participation from China-Singapore Group, Xi'an Finance, and Xi'an Talent Development Fund. Existing shareholders continued to increase their investment. The funds will be used to iterate and optimize Temporal Interference (TI) stimulation technology and accelerate the registration of products for various indications.Predictive AI Telemedicine Service Provider Sehat Kahani Raises $2.7 Million in Series A FundingOn December 25, Sehat Kahani, a predictive AI telemedicine service provider, secured $2.7 million in Series A funding, led by Singapore-based health technology fund Amaanah Circle. Sehat Kahani will use the newly acquired funds to apply predictive artificial intelligence to telemedicine and deliver precision healthcare services.Certainly Health, a healthcare booking service provider, secures $2.3 million in fundingOn December 13, Certainly Health, a healthcare booking service provider, secured $2.3 million in funding led by Pacific 8 Ventures, Y-Combinator, along with other institutions and angel investors. The funds will be used to expand the team and enhance the company’s product offerings. Patients input their insurance details and reasons for visiting, and Certainly uses machine learning to predict out-of-pocket costs, with any excess fees covered by Certainly.AI Drug Discovery Company Peptris Technologies Secures $1 Million in Seed FundingOn December 22, AI-driven drug discovery company Peptris Technologies secured $1 million in seed funding, led by Speciale Invest. The company focuses on AI-powered drug research and will use the newly acquired funds to expand its research scope to include rare diseases, as well as enhance its current R&D progress in cancer and inflammation.02 Digital Health Industry Dynamics
Gilead Sciences Announces Collaboration Agreement with CompugenOn December 20, Gilead Sciences announced a collaboration agreement with Compugen, obtaining exclusive rights to its potential "first-in-class" preclinical Interleukin-18 Binding Protein (IL-18BP) targeted antibody COM503. The total deal could reach up to $848 million.GSK Acquires Hansoh Pharma's ADC for Over $1.7 BillionRecently, Hansoh Pharma announced that it has reached a licensing agreement with GSK. Under the agreement, GSK will be granted an exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop, manufacture, and commercialize the investigational Antibody-Drug Conjugate (ADC) HS-20093. According to the licensing agreement, Shanghai Hansoh Biomedical will receive an upfront payment of $185 million and is eligible to receive up to $1.525 billion in milestone payments for the product.C4 Therapeutics Announces Collaboration with MSDOn December 12, C4 Therapeutics announced today that it has signed an exclusive license and collaboration agreement with MSD to develop antibody-conjugated protein degradation drugs, an emerging therapeutic modality designed to selectively target and degrade disease-causing proteins in cancer cells. If MSD exercises all its options to expand the collaboration, C4T is eligible to receive up to approximately $2.5 billion in potential payments throughout the partnership.03 Overview of Global Digital Health M&ABristol-Myers Squibb to Acquire RayzeBio, Expanding Oncology Drug PortfolioOn December 26, Bristol Myers Squibb announced that it would acquire RayzeBio for approximately $4.1 billion in a deal at a significant premium, aiming to comprehensively expand its oncology drug portfolio. RayzeBio is a vertically integrated radiopharmaceutical company dedicated to developing targeted radiopharmaceuticals for the treatment of various cancer types. Its research and development focuses on a series of targeted therapies for diagnosing and treating tumors.Bristol-Myers Squibb Acquires Karuna for $14 BillionOn December 22, Bristol Myers Squibb and Karuna Therapeutics announced that they had reached a definitive acquisition agreement. Under the terms of the agreement, Bristol Myers Squibb agreed to acquire Karuna Therapeutics for a total amount of approximately $14 billion. Through this acquisition, Bristol Myers Squibb will obtain Karuna's potential "first-in-class" therapy, KarXT, for which a new drug application for the treatment of adult schizophrenia has been accepted by the U.S. FDA.Artery Network/Arterial Orange Industry Think Tank/China Renaissance/CGC/Rock Health/Mobile Health News/FierceHealth, etc.
Compiled by: Zhang Qiankun
